TBVI continuously works to support the development of new TB vaccine candidates. We invite and encourage vaccine developers to share updates of their work so that we can update the pipeline table. Please contact TBVI at info@tbvi.eu.
Please note that the overview of candidates in the preclinical phase is not complete as it shows preclinical candidates in which TBVI is involved. For a comprehensive overview, please consult the website of the Working Group on New TB Vaccines.
The current TB vaccine pipeline of candidates supported by TBVI (last update January 2024), is shown below:
TBVI provides technical support for product and clinical development to TB vaccine researchers and developers.
TBVI has initiated and coordinated the realisation of a joint publication regarding preferred product characteristics (PPC) for therapeutic vaccines to improve tuberculosis treatment outcomes. This PPC is a result of a consensus generating consultation process from the WHO, TBVI and IAVI with input from experts within the TB field and beyond. To read the full publication, please follow the link: Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organization consultations.